Entering text into the input field will update the search result below

NervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291.
  • The company said that

Recommended For You

Related Stocks

SymbolLast Price% Chg
NGENF
--
NGEN:CA
--